Showing 409 results

Filters Content type: News, Editors' picks, About HIV Topic: Changing treatment

A change of HIV treatment may be necessary because of side-effects, the development of drug resistance, treatment not being fully effective or because of interactions between HIV drugs and other medications.

Access to healthcare

Top 5 stories on HIV in Africa from CROI 2023

News
10 March 2023
Weight gain & lipodystrophy

Weight loss after treatment switch more likely for those with higher body mass

News
28 February 2023
New & experimental HIV treatments

White blood cell changes on islatravir do not lead to a higher risk of infections

News
28 February 2023
Injectable & long-acting HIV treatment

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

Editor's pick
ViiV press release
23 February 2023
Weight gain & lipodystrophy

Switching to injectable cabotegravir and rilpivirine rarely affects body weight

News
23 February 2023
Changing treatment

Dolutegravir plus darunavir superior to three-drug darunavir combination in second-line treatment

News
23 February 2023
Access to healthcare

Darunavir/ritonavir (DRV/r) Advocacy!

Editor's pick
AfroCAB
27 January 2023
Drug interactions & pharmacokinetics

Protease-to-Integrase Switch Greatly Reduces HIV Drug-Drug Interaction Risk

Editor's pick
TheBodyPro
25 January 2023
Injectable & long-acting HIV treatment

I Stopped Taking My HIV Pills

Editor's pick
POZ
20 January 2023
Weight gain & lipodystrophy

Switching from TAF to older tenofovir may halt or reverse weight gain and lipid increases

News
23 December 2022
Changing treatment

Second-line HIV treatment durable for eight years in Uganda

News
17 November 2022
Injectable & long-acting HIV treatment

‘Real world’ injectable treatment halves patient dissatisfaction, with only two viral failures in first six months

News
1 November 2022
Starting treatment

After viral rebound, dolutegravir-based treatment more likely to suppress HIV

News
31 October 2022
Resistance

Low-level HIV and viral load blips are important warning signals, European study finds

News
19 October 2022
Resistance

Are people with a shorter history of viral suppression at greater risk of failure of dolutegravir/lamivudine?

News
6 October 2022
Changing treatment

A Switch to B/F/TAF Keeps HIV Suppressed, Even With Mutation

Editor's pick
Medscape (requires free registration)
20 September 2022
Side effects

Go Slow Before Switching HIV Meds Due to Metabolic Effects

Editor's pick
Infectious Disease Special Edition
14 September 2022
Changing treatment

Inflammatory Biomarkers in HIV Support Safety of Switching to 2-Drug Antiretroviral Therapy

Editor's pick
Infectious Disease Advisor
8 September 2022
TB epidemiology

Zambian patients on dolutegravir and recycled tenofovir regimens have high risk of TB even after switch

News
31 August 2022
Injectable & long-acting HIV treatment

Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression

News
23 August 2022
Treatment guidelines

World’s largest HIV treatment programme could shift almost entirely to WHO-preferred first line regimen

News
7 June 2022
Starting treatment

Recommended treatments for HIV

About HIV
May 2022
Changing treatment

‘The Devil You Know’: Many People Over 50 Are Taking Outdated ART, Despite Side Effects

Editor's pick
TheBodyPro
27 April 2022
Changing treatment

Outcomes of HIV Virologic Suppression After Switching to Dolutegravir/Lamivudine

Editor's pick
Infectious Disease Advisor
28 March 2022